Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET

Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268 healthy c...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaccarino, Leonardo, Sala, Arianna, Perani, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562030/
https://www.ncbi.nlm.nih.gov/pubmed/31211176
http://dx.doi.org/10.1002/acn3.782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562030/
https://www.ncbi.nlm.nih.gov/pubmed/31211176
http://dx.doi.org/10.1002/acn3.782

Ejemplares similares